Analytical quality by design (AQbD) in pharmaceutical development

American Pharmaceutical Review

Volumn 16, Issue 5, 2013, Pages

  Reid, George L ^a   Morgado, James ^a   Barnett, Kimber ^a   Harrington, Brent ^a   Wang, Jian ^a   Harwood, Jeff ^a   Fortin, David ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; ANALYTICAL QUALITY BY DESIGN; ARTICLE; CAPILLARY ELECTROPHORESIS; DRUG INDUSTRY; DRUG MANUFACTURE; HUMAN; PH; QUALITY CONTROL; REVERSED PHASE LIQUID CHROMATOGRAPHY; RISK ASSESSMENT; RISK FACTOR; THIN LAYER CHROMATOGRAPHY;

EID: 84885652372     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. International Conference on Harmonization (ICH)Q8(R2): Pharmaceutical Development (August 2009).
2. International Conference on Harmonization (ICH)Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/ Biological Entities) (May2011).
3. Borman, P.; Nethercote, P.; Chatfield, M.; Thompson, D.; Truman K. The Application of Quality by Design to Analytical Methods. Pharm. Tech. 2007,31(12) 142-152.
4. Schweitzer, M.; Pohl, M.; Hanna-Brown, M.; Nethercote, P.; Borman, P.; Hansen, G.; Smith, K.; Larew J. Implications and Opportunities of Applying QbD Principles to Analytical Measurements. Pharm. Tech. 2010,34 (2) 52-59.
5. Vogt, F.G.; Kord AS. Development of Quality-By-Design Analytical Methods. J. Pharm. Sci. 2011,100(3), 797-812.
6. Bhatt, D.A; Rane, S.I. QbD Approach to Analytical RP-HPLC Method Development and its Validation. Int. J. Pharm. and Pharm. Sci. 2011,3(1) 179-187.
7. Krull, I.; Swartz, M.; Turpin, J.; Lukulay, P.H.; Verseput, R. AQuality-by-Design Methodology for Rapid LC Method Development, Part I. LCGC N. Am. 2008,26,1190-1197.
8. Krull, I.; Swartz, M.; Turpin, J.; Lukulay, P.H.; Verseput, R. AQuality-by-Design Methodology for Rapid LC Method Development, Part II. LCGC N. Am. 2009,27,48-61.
9. Meyer, C; Soldo, T.; Kettenring, U. Highlights of Analytical Chemistryin Switzerland. Chimia 2010,64(11), 825.
10. Graul, T.W.; Barnett, K.L.; Bale, S.J.; Gill, I; Hanna-Brown M. in Chemical Engineers in the Pharmaceutical Industry: R&D to Manufacturing; am Ende, D.J. Ed.; John Wiley & Sons: New York, 2011, pp 545-562.
11. Ling S.; McBrien, M. AQuality by Design Approach to Chromatographic Method Development. LCGC: The Column 2011,7(5), 16-20.
12. Molnar, I.; Rieger, H.-J.; Monks, K.E. Aspects of the "Design Space" in high pressure liquid chromatography method development. J. Chromatogr. A2010,1217,3193-3200.
13. Karmarkar, S.; Garber, R.; Genchanok, Y; George, S.; Yang.X; Hammond, R. Quality by Design (QbD) Based Development of a Stability Indicating HPLC Method for Drug and Impurities. J. Chromatogr. Sci. 2011,49,439-446.
14. Monks, K.E.; Rieger, H.-J.; Molnar, I. Expanding the term "Design Space" in high performance liquid chromatography (I). J. Pharm. Biomed. Anal. 2011,56 (5), 874-879.
15. Reid, G.L; Cheng, G; Fortin, D.T; Harwood, J.H.; Morgado, J.E.; Wang, J.; Xue, G. Reversed- Phase Liquid Chromatographic Method Development in an Analytical Quality by Design Framework, J. of Liq. Chromatogr. Relat. Tech., 2013, DOI:10.1080/10826076.2013.765457.
16. Monks, K.; Molnar, I.; Rieger, H.-J.; Bogati, B.; Szabo, E. Quality by Design: Multidimensional exploration of the design space in high performance liquid chromatography method development for better robustness before validation. J. Chromatogr. A2012,1232,218-230.
17. Orlandini, S.; Pinzauti S.; Furlanetto S. Application of quality by design to the development of analytical separation methods, Anal Bioanal Chem. 2013,405,443-450
18. Musters, J.; van den Bos, L.; Kellenbach, E. Applying QbD Principles To Develop a Generic UHPLC Method Which Facilitates Continual Improvement and Innovation Throughout the Product Lifecycle for a Commercial API. Org. Process Res. Dev. 2013,17,87-96.
19. Rozet, E.; Lebrun, P.; Debrus, B.; Boulanger, B.; Hubert P. Design Spaces for analytical Methods. Trends in Analytical Chemistry, 2013,42,157-167.
20. Kochling, J.; Bridgewater, J.; Naji R. in Pharmaceutical Stability Testing to Support Global Markets; Huynh-Ba, K. Ed.; Springer: New York, 2010, pp 169-179.
21. Cecil, Todd; Acceptable Analytical Method Variation - Setting System Suitability Requirements, Pittcon 2013
22. Barnett, K.L.; Harrington, B.;. Graul, T.W. in Liquid Chromatography Applications; Fanali, S.; Haddad, P.R.; Poole, C.F. Eds; Elsevier, 2013, pp 57-73.
23. Huberta, Ph.; Nguyen-Huub, J.-J.; Boulangerc, B.; Chapuzetd, E.; Chiapa, P.; Cohene, N.; Compagnonf, P.-A; Dewéc, W.; Feinbergg, M.; Lallierh, M.; Laurentiei, M.; Mercierd, N.; Muzardj, G.; Nivetk, C; Valatl, L. Harmonization of strategies for the validation of quantitative analytical procedures ASFSTP proposal-part I. J. Pharm. Biomed. Anal. 2004,36,579-586.
24. Ahuja, S. and Jespersen, N. Modern Instrumental Analysis, Elsevier, Amsterdam, 2006.
25. Skoog, DA, Holler, F.J, Crouch, S.R. Principles of Instrumental Analysis, Thomson Learning, 2006.
26. Ahuja, S.; Scypinski, S. Handbook of Modern Pharmaceutical Analysis, Second Edition, Academic Press, 2011.
27. Nickerson, B. Sample Preparation of Pharmaceutical Dosage Forms, Springer, 2011.
28. Ahuja, S.; Dong, M. Handbook of Pharmaceutical Analysis by HPLC, Elsevier, 2005.
29. Sasic, S.; Ozaki, Y. Raman, Infrared, and Near-Infrared Chemical Imaging, John Wiley & Sons, 2011.
30. Burns, DA; Ciurczak, E.W. Handbook of Near-Infrared Analysis, Third Edition, CRC Press, 2007.
31. Wawer, I.; Diehl B. NMR Spectroscopy in Pharmaceutical Analysis, Elsevier, 2011.
32. Reid, G.L., Ward, H., Palm AS., Muteki, K. Process Analytical Technology (PAT) in Pharmaceutical Development, Amer. Pharm. Rev. 2012,15(4), 49-55.
33. International Conference on Harmonization (ICH)Q9: Quality Risk Management (November 2005).
34. Myers, R.H; Montgomery, D.C. Response Surface Methodology: Process and Product Optimization using Designed Experiments, Second Edition, New York: John Wiley & Sons, 1995.
35. QbD Considerations for Analytical Methods - FDA Perspective, presented atthe IFPAC Annual Meeting, Baltimore, January25,2013, Sharmista Chatterjee, Ph.D., CMC Lead for QbD ONDQA/CDER/FDA.